These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34825103)

  • 21. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
    Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
    Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
    Marsden J; Tai B; Ali R; Hu L; Rush AJ; Volkow N
    Addiction; 2019 Aug; 114(8):1346-1353. PubMed ID: 30614096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
    Cioe K; Biondi BE; Easly R; Simard A; Zheng X; Springer SA
    J Subst Abuse Treat; 2020 Dec; 119():108146. PubMed ID: 33138929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
    Miller WA; Gordon AJ; Clothier BA; Ackland PE; Bounthavong M; Garcia C; Kenny ME; Noorbaloochi S; Hagedorn HJ
    Implement Res Pract; 2023; 4():26334895231199463. PubMed ID: 37790176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of primary care engagement with initiation and continuation of medication treatment for opioid use disorder among persons with a history of injection drug use.
    Sosnowski DW; Feder KA; Genberg BL; Mehta SH; Kirk GD
    Drug Alcohol Depend; 2024 Sep; 262():111383. PubMed ID: 38986240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
    Johnson K; Hills H; Ma J; Brown CH; McGovern M
    Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
    [No Abstract]   [Full Text] [Related]  

  • 32. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
    Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
    J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
    Viera A; Bromberg DJ; Whittaker S; Refsland BM; Stanojlović M; Nyhan K; Altice FL
    Epidemiol Rev; 2020 Jan; 42(1):41-56. PubMed ID: 32239206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19 and treating incarcerated populations for opioid use disorder.
    Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
    J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
    Will J; Abare M; Olson M; Chyorny A; Wilhelm-Leen E
    J Subst Abuse Treat; 2022 Oct; 141():108838. PubMed ID: 35868162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.